Paul Choi
Stock Analyst at Goldman Sachs
(3.67)
# 556
Out of 4,829 analysts
110
Total ratings
55.07%
Success rate
4.69%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHAT Phathom Pharmaceuticals | Maintains: Neutral | $10 → $5 | $3.14 | +59.24% | 10 | May 2, 2025 | |
| ARVN Arvinas | Maintains: Neutral | $12 → $8 | $6.61 | +21.03% | 3 | May 2, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $60 → $52 | $35.02 | +48.49% | 2 | Apr 17, 2025 | |
| VIR Vir Biotechnology | Maintains: Buy | $28 → $21 | $5.09 | +312.98% | 8 | Apr 17, 2025 | |
| URGN UroGen Pharma | Maintains: Neutral | $22 → $16 | $10.38 | +54.14% | 3 | Apr 17, 2025 | |
| RGNX REGENXBIO | Maintains: Neutral | $14 → $12 | $7.52 | +59.57% | 3 | Apr 17, 2025 | |
| GOSS Gossamer Bio | Maintains: Buy | $8 → $7 | $1.11 | +530.63% | 5 | Apr 17, 2025 | |
| ESPR Esperion Therapeutics | Maintains: Neutral | $4 → $3 | $0.80 | +275.85% | 9 | Apr 17, 2025 | |
| DVAX Dynavax Technologies | Maintains: Sell | $12 → $10 | $9.41 | +6.27% | 4 | Apr 17, 2025 | |
| AMRN Amarin Corporation | Maintains: Sell | $20 → $7 | $10.38 | -32.56% | 8 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $151.46 | +48.55% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $143 | $81.74 | +74.94% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $42 | $44.23 | -5.04% | 7 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $85 → $60 | $31.70 | +89.30% | 2 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $14.21 | +33.71% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $32 | $26.06 | +22.79% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $50 | $34.17 | +46.33% | 6 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $4.20 | +352.38% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $16 → $2 | $0.31 | +549.35% | 7 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $0.88 | +2,732.86% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $4 | $0.33 | +1,119.51% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $20.24 | +739.92% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $2.91 | +174.91% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $33 | $29.34 | +12.47% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $112 | $46.26 | +142.11% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $115.71 | +16.67% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $18 → $20 | $0.59 | +3,297.32% | 2 | Mar 30, 2020 |
Phathom Pharmaceuticals
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $3.14
Upside: +59.24%
Arvinas
May 2, 2025
Maintains: Neutral
Price Target: $12 → $8
Current: $6.61
Upside: +21.03%
Xenon Pharmaceuticals
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $35.02
Upside: +48.49%
Vir Biotechnology
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $5.09
Upside: +312.98%
UroGen Pharma
Apr 17, 2025
Maintains: Neutral
Price Target: $22 → $16
Current: $10.38
Upside: +54.14%
REGENXBIO
Apr 17, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $7.52
Upside: +59.57%
Gossamer Bio
Apr 17, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $1.11
Upside: +530.63%
Esperion Therapeutics
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $0.80
Upside: +275.85%
Dynavax Technologies
Apr 17, 2025
Maintains: Sell
Price Target: $12 → $10
Current: $9.41
Upside: +6.27%
Amarin Corporation
Apr 17, 2025
Maintains: Sell
Price Target: $20 → $7
Current: $10.38
Upside: -32.56%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $151.46
Upside: +48.55%
Dec 18, 2024
Initiates: Buy
Price Target: $143
Current: $81.74
Upside: +74.94%
Dec 4, 2024
Maintains: Sell
Price Target: $32 → $42
Current: $44.23
Upside: -5.04%
Aug 13, 2024
Downgrades: Neutral
Price Target: $85 → $60
Current: $31.70
Upside: +89.30%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $14.21
Upside: +33.71%
Jul 26, 2023
Maintains: Buy
Price Target: $22 → $32
Current: $26.06
Upside: +22.79%
Jul 18, 2023
Maintains: Buy
Price Target: $29 → $50
Current: $34.17
Upside: +46.33%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $4.20
Upside: +352.38%
Jun 27, 2023
Maintains: Sell
Price Target: $16 → $2
Current: $0.31
Upside: +549.35%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $0.88
Upside: +2,732.86%
May 24, 2022
Maintains: Neutral
Price Target: $10 → $4
Current: $0.33
Upside: +1,119.51%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $20.24
Upside: +739.92%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $2.91
Upside: +174.91%
Mar 22, 2021
Assumes: Buy
Price Target: $33
Current: $29.34
Upside: +12.47%
Mar 22, 2021
Assumes: Buy
Price Target: $112
Current: $46.26
Upside: +142.11%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $115.71
Upside: +16.67%
Mar 30, 2020
Upgrades: Neutral
Price Target: $18 → $20
Current: $0.59
Upside: +3,297.32%